Compare · KEQU vs NTRA
KEQU vs NTRA
Side-by-side comparison of Kewaunee Scientific Corporation (KEQU) and Natera Inc. (NTRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- KEQU operates in Industrials, while NTRA operates in Health Care - the two are in different parts of the market.
- NTRA is the larger of the two at $37.52B, about 363.0x KEQU ($103.4M).
- Over the past year, KEQU is down 37.6% and NTRA is up 89.7% - NTRA leads by 127.3 points.
- NTRA has been more active in the news (11 items in the past 4 weeks vs 2 for KEQU).
- NTRA has more recent analyst coverage (25 ratings vs 0 for KEQU).
- Company
- Kewaunee Scientific Corporation
- Natera Inc.
- Price
- $36.47-1.45%
- $261.88-1.03%
- Market cap
- $103.4M
- $37.52B
- 1M return
- +6.31%
- +0.74%
- 1Y return
- -37.64%
- +89.70%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- News (4w)
- 2
- 11
- Recent ratings
- 0
- 25
Kewaunee Scientific Corporation
Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. It operates in two segments, Domestic and International. The company's products include steel, wood, laminate furniture, fume hoods, biological safety cabinets, laminar flow and ductless hoods, adaptable modular and column systems, moveable workstations and carts, epoxy resin worksurfaces, sinks, and accessories and related design services. Its laboratory products are used in chemistry, physics, biology, and other general science laboratories in the pharmaceutical, biotechnology, industrial, chemical, commercial, educational, government, and health care markets; technical products are used in facilities manufacturing computers and light electronics and by users of computer and networking furniture; and laminate caseworks that are used in educational, healthcare, and industrial applications. The company sells its products primarily through dealers, commissioned agents, and a national distributor, as well as through competitive bids submitted by the company and its subsidiaries in Singapore, India, and China. Kewaunee Scientific Corporation was founded in 1906 and is headquartered in Statesville, North Carolina.
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Latest KEQU
- SEC Form DEFA14A filed by Kewaunee Scientific Corporation
- SEC Form DEF 14A filed by Kewaunee Scientific Corporation
- SVP, People & Culture Phillips Elizabeth D converted options into 6,656 shares, returned $181,069 worth of shares to the company (4,995 units at $36.25) and covered exercise/tax liability with 793 shares, increasing direct ownership by 11% to 9,116 units (SEC Form 4)
- SVP, IT & Engineering Ranade Mandar converted options into 7,227 shares, returned $65,250 worth of shares to the company (1,800 units at $36.25) and covered exercise/tax liability with 1,877 shares, increasing direct ownership by 28% to 16,215 units (SEC Form 4)
- SVP, Sales & Marketing Dev Noble Ryan S. returned $108,750 worth of shares to the company (3,000 units at $36.25), covered exercise/tax liability with 1,809 shares and converted options into 7,206 shares, increasing direct ownership by 17% to 16,240 units (SEC Form 4)
- SVP, Manufacturing Operations Batdorff Douglas J. converted options into 7,451 shares, returned $203,326 worth of shares to the company (5,609 units at $36.25) and covered exercise/tax liability with 851 shares, increasing direct ownership by 14% to 8,170 units (SEC Form 4)
- Chief Financial Officer Gardner Donald T. Iii converted options into 21,265 shares, returned $435,000 worth of shares to the company (12,000 units at $36.25) and covered exercise/tax liability with 4,027 shares, increasing direct ownership by 55% to 14,802 units (SEC Form 4)
- President & CEO Hull Thomas David Iii converted options into 54,388 shares, returned $616,250 worth of shares to the company (17,000 units at $36.25) and covered exercise/tax liability with 16,243 shares, increasing direct ownership by 64% to 54,145 units (SEC Form 4)
- SEC Form 10-K filed by Kewaunee Scientific Corporation
- SEC Form 4 filed by SVP, People & Culture Phillips Elizabeth D
Latest NTRA
- Signatera™ MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study
- Director Chapman Rowan E sold $37,101 worth of shares (135 units at $274.82) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 4,663 units (SEC Form 4)
- CO-FOUNDER Sheena Jonathan sold $410,825 worth of shares (1,500 units at $273.88) as part of a pre-agreed trading plan (SEC Form 4)
- Finalized MolDx LCD Includes Expanded Coverage for Natera’s Prospera™ Portfolio
- CO-FOUNDER Sheena Jonathan sold $836,898 worth of shares (3,150 units at $265.68) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 246,202 units (SEC Form 4)
- Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers
- EXECUTIVE CHAIRMAN Rabinowitz Matthew sold $280,000 worth of shares (1,000 units at $280.00) as part of a pre-agreed trading plan (SEC Form 4)
- SEC. AND CHIEF LEGAL OFFICER Rabinowitz Daniel sold $4,574,431 worth of shares (16,800 units at $272.29) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 172,294 units (SEC Form 4)
- PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $818,710 worth of shares (3,000 units at $272.90) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 134,643 units (SEC Form 4)
- Natera Inc. filed SEC Form 8-K: Leadership Update